Presant CA - Search Results

1

Cyclophosphamide plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) with or without Corynebacterium parvum in metastatic malignant melanoma.

Presant CA, Bartolucci AA, Smalley RV, Vogler WR. Presant CA, et al. Cancer. 1979 Sep;44(3):899-905. doi: 10.1002/1097-0142(197909)44:3<899::aid-cncr2820440317>3.0.co;2-y. Cancer. 1979. PMID: 383276 Clinical Trial.

2

Phase I/II trial of human recombinant granulocyte-colony-stimulating factor (filgrastim) and escalating doses of cyclophosphamide, mitoxantrone, and 5-FU in the treatment of advanced breast cancer.

Budd GT, Atiba J, Silver RT, Palmer G, Armstrong S, Otto K, Presant C. Budd GT, et al. J Cancer Res Clin Oncol. 1999 Aug-Sep;125(8-9):500-4. doi: 10.1007/s004320050308. J Cancer Res Clin Oncol. 1999. PMID: 10480343 Clinical Trial.

3

Ineffectiveness of adjuvant chemotherapy using DTIC and cyclophosphamide in patients with resectable metastatic melanoma.

Balch CM, Murray D, Presant C, Bartolucci AA. Balch CM, et al. Surgery. 1984 Apr;95(4):454-9. Surgery. 1984. PMID: 6369594 Clinical Trial.

4

Buserelin as primary therapy in advanced prostatic carcinoma.

Presant CA, Soloway MS, Klioze SS, Kosola JW, Yakabow AL, Mendez RG, Kennedy PS, Wyres MR, Naessig VL, Ford KS, et al. Presant CA, et al. Cancer. 1985 Nov 15;56(10):2416-9. doi: 10.1002/1097-0142(19851115)56:10<2416::aid-cncr2820561013>3.0.co;2-#. Cancer. 1985. PMID: 3930064

5

Buserelin treatment of advanced prostatic carcinoma. Long-term follow-up of antitumor responses and improved quality of life.

Presant CA, Soloway MS, Klioze SS, Yakabow A, Presant SN, Mendez RG, Kennedy PS, Wyres MR, Naessig VL, Todd B, et al. Presant CA, et al. Among authors: presant sn. Cancer. 1987 May 15;59(10):1713-6. doi: 10.1002/1097-0142(19870515)59:10<1713::aid-cncr2820591006>3.0.co;2-8. Cancer. 1987. PMID: 3103904

6

Remission maintenance for acute nonlymphocytic leukemia: cytosine arabinoside plus 6-thioguanine versus a sequence of drug regimens.

Presant CA, Berger NA, Klahr C, Phillips GL. Presant CA, et al. Cancer. 1980 Jul 1;46(1):22-8. doi: 10.1002/1097-0142(19800701)46:1<22::aid-cncr2820460104>3.0.co;2-p. Cancer. 1980. PMID: 6930320 Clinical Trial.

7

Prognostic factors in metastatic malignant melanoma: The Southeastern Cancer Study Group Experience.

Presant CA, Bartolucci AA. Presant CA, et al. Cancer. 1982 May 15;49(10):2192-6. doi: 10.1002/1097-0142(19820515)49:10<2192::aid-cncr2820491035>3.0.co;2-r. Cancer. 1982. PMID: 6176309 Clinical Trial.

8

Metastatic sarcomas: chemotherapy with adriamycin, cyclophosphamide, and methotrexate alternating with actinomycin D, DTIC, and vincristine.

Presant CA, Lowenbraun S, Bartolucci AA, Smalley RV. Presant CA, et al. Cancer. 1981 Feb 1;47(3):457-65. doi: 10.1002/1097-0142(19810201)47:3<457::aid-cncr2820470306>3.0.co;2-g. Cancer. 1981. PMID: 7225999 Clinical Trial.

9

Biological characterization of a prolonged antileukemic effect of 5-azacytidine.

Presant CA, Valeriote F, Vietti TJ. Presant CA, et al. Cancer Res. 1977 Feb;37(2):376-81. Cancer Res. 1977. PMID: 64294

10

A randomized prospective clinical trial of adjuvant C. parvum immunotherapy in 260 patients with clinically localized melanoma (Stage I): prognostic factors analysis and preliminary results of immunotherapy.

Balch CM, Smalley RV, Bartolucci AA, Burns D, Presant CA, Durant JR. Balch CM, et al. Among authors: presant ca. Cancer. 1982 Mar 15;49(6):1079-84. doi: 10.1002/1097-0142(19820315)49:6<1079::aid-cncr2820490604>3.0.co;2-x. Cancer. 1982. PMID: 7037155 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results